Schall Thomas J. 4

What Happened Thomas J. Schall, a director of Immuneering Corp (IMRX), received a derivative equity award on June 11, 2026 for 33,350 shares. The filing reports the grant as an option award (acquisition code A) with an acquisition price of $0.00; no shares were sold. This is a compensation grant rather than an open-market purchase or sale.

Key Details

• Transaction date: June 11, 2026 (report filed same day).
• Award: 33,350-share option (derivative) reported at $0.00 acquisition cost.
• Vesting: Option vests and becomes exercisable in equal monthly installments over one year beginning July 11, 2026; fully vested on June 11, 2027 or on the date of the 2027 annual meeting of stockholders, whichever is earlier (see footnote).
• Shares owned after transaction: Not specified in the provided summary of the filing.
• Filing timeliness: Reported on the same date as the transaction — no late filing indicated.

Context This was a grant of options as compensation to a board member, not a market purchase or sale. The option must vest over the coming year before it can be exercised; exercising would typically require paying any exercise price specified in the full grant terms (not shown here). Compensation grants are common for directors and do not by themselves indicate a buy/sell signal.